These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24406339)

  • 1. Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice.
    Hemmeryckx B; Swinnen M; Gallacher DJ; Rong Lu H; Roger Lijnen H
    Eur J Pharmacol; 2014 Jan; 723():175-80. PubMed ID: 24406339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
    Poucher SM; Cheetham S; Francis J; Zinker B; Kirby M; Vickers SP
    Diabetes Obes Metab; 2012 Oct; 14(10):918-26. PubMed ID: 22564773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
    Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
    Ye Y; Keyes KT; Zhang C; Perez-Polo JR; Lin Y; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1454-65. PubMed ID: 20207816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
    Picatoste B; Ramírez E; Caro-Vadillo A; Iborra C; Ares-Carrasco S; Egido J; Tuñón J; Lorenzo O
    PLoS One; 2013; 8(10):e78330. PubMed ID: 24302978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
    Muscelli E; Casolaro A; Gastaldelli A; Mari A; Seghieri G; Astiarraga B; Chen Y; Alba M; Holst J; Ferrannini E
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2818-26. PubMed ID: 22685234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
    Badole SL; Chaudhari SM; Bagul PP; Mahamuni SP; Khose RD; Joshi AC; Raut CG; Zanwar AA
    PLoS One; 2013; 8(8):e72817. PubMed ID: 24023648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
    Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
    Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
    Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
    J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
    Harashima SI; Tanaka D; Yamane S; Ogura M; Fujita Y; Murata Y; Seike M; Koizumi T; Aono M; Wang Y; Inagaki N
    Horm Metab Res; 2013 Mar; 45(3):231-8. PubMed ID: 22972180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA
    Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
    Nunez DJ; Bush MA; Collins DA; McMullen SL; Gillmor D; Apseloff G; Atiee G; Corsino L; Morrow L; Feldman PL
    PLoS One; 2014; 9(4):e92494. PubMed ID: 24699248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.